Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scribe Therapeutics, Inc.SCTX · Entity 5494 | Chief Financial Officer | March 13, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scribe Therapeutics, Inc.
Report date March 13, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,333 |
Reported balance
After 2026-07-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-23 · Purchase · Acquired 1,333 · Balance 1,333 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 1,333 |
Reported balance
After 2026-07-23 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-23 · Purchase · Acquired 1,333 · Balance 1,333 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2036-03-12 | Direct | 8,909 |
Reported balance
After 2026-03-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-13 · Grant · Acquired 8,909 · Balance 8,909 F1: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a). F2: The option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-07-22 | Direct | 109,426 |
Reported balance
After 2026-07-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-23 · Grant · Acquired 109,426 · Balance 109,426 F3: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Performance-based Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-07-22 | Direct | 109,426 |
Reported balance
After 2026-07-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-23 · Grant · Acquired 109,426 · Balance 109,426 F4: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
F2: The option is fully vested.
F3: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 28, 2026 01:20 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantPerformance-based Stock Option (Right to Buy) · Derivative | 109,426 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0002127908-26-000004 · form4-07282026_010722.xml · derivative · entry 5 Parrot David · CIK 0002127908 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,426 Underlying: Common Stock · 109,426 shares Expires 2036-07-22 F4 · derivative.exercise_date: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 23, 2026 Filed Jul 28, 2026 01:20 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantStock Option (Right to Buy) · Derivative | 109,426 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0002127908-26-000004 · form4-07282026_010722.xml · derivative · entry 4 Parrot David · CIK 0002127908 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,426 Underlying: Common Stock · 109,426 shares Expires 2036-07-22 F3 · derivative.exercise_date: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 23, 2026 Filed Jul 28, 2026 01:20 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | PurchaseCommon Stock | 1,333 | $15.00 | $19,995.00 |
DisclosureSEC source: 0002127908-26-000004 · form4-07282026_010722.xml · nonDerivative · entry 2 Parrot David · CIK 0002127908 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Child Disclosed balance after: 1,333 Read SEC document |
| July 23, 2026 Filed Jul 28, 2026 01:20 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | PurchaseCommon Stock | 1,333 | $15.00 | $19,995.00 |
DisclosureSEC source: 0002127908-26-000004 · form4-07282026_010722.xml · nonDerivative · entry 1 Parrot David · CIK 0002127908 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,333 Read SEC document |
| March 13, 2026 Filed Jul 28, 2026 01:20 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantStock Option (Right to Buy) · Derivative | 8,909 | $0.00 Strike: $19.13 | $0.00 |
DisclosureSEC source: 0002127908-26-000004 · form4-07282026_010722.xml · derivative · entry 3 Parrot David · CIK 0002127908 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,909 Underlying: Common Stock · 8,909 shares Expires 2036-03-12 F1 · date: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a). F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.